The expert advisory group for this health technology assessment (HTA) was established to assess the clinical and economic impact of providing C-reactive protein point-of-care testing to inform the prescribing of antibiotics for patients presenting with symptoms of acute respiratory tract infections (RTIs) in primary care. The public and/or patient (PPI) representatives were involved in supporting HIQA to fulfil its health technology assessment function. All expert advisory group members provided input into the process (for example, forming the terms of reference, drafting key considerations in the report, interpreting research findings) and they also provide peer review of the project report. The public and/or patient representatives were engaged from July 2018 to May 2019. The expert advisory group met twice during this period.
The expert advisory group for health technology assessment (HTA) of C-reactive protein point-of-care testing to guide antibiotic prescribing comprised of 18 members, including two patient and/or public (PPI) representatives. The PPI representative were identified by a relevant stakeholder organisation, who nominated a representative to participate in the expert advisory group for the duration of the project. There was no specific eligibility criteria. The expert advisory group members were provided with draft written terms of reference for their role, and they were involved in finalisation process.